Drug recall · January 14, 2026
Tri-Moxi+¿ recall
Why: Presence of particulate matter - Glass like particles.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
- Lots / codes
Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
- Quantity
- 314 boxes of 6,280 pre-filled syringes
- Company
- Imprimis NJOF, LLC, Ledgewood, NJ
- Distribution
- U.S Nationwide
- Initiated
- December 18, 2025 · Voluntary: Firm initiated
- Classified
- January 2, 2026
- Reported
- January 14, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Triamcinolone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.